Radiotherapy Market – By Product Type, By Application, By End Use – Global Forecast 2025 – 2034

Radiotherapy Market Size

The global radiotherapy market was estimated at USD 7.4 billion in 2024. The market is expected to grow from USD 7.7 billion in 2025 to USD 13 billion in 2034, at a CAGR of 5.9% during the forecast period.
 

Radiotherapy is a medical treatment that is used to treat cancer and shrink tumors by using high doses of radiation, often including radiation such as gamma rays, X-rays, or charged particles that target and damage the cancerous cell's DNA, preventing them from further cell division and growth. This treatment can be undertaken by two methods: internally through placing radioactive material inside the body near the cancer cells (brachytherapy), or externally with the help of an instrument known as a linear accelerator (external beam radiotherapy).
 

The growth of the market is highly attributed to the rising prevalence of cancer across the world. For instance, as per the estimates from the Cancer Atlas, the global prevalence of cancer is projected to increase by 60% in 2040, owing to the aging population across the globe, which is equivalent to 29.4 million new cancer cases in 2040 as compared to 18.1 million cancer cases diagnosed in the year 2018. Thus, the rising burden of cancer, due to factors such as lifestyle changes, aging population, and environmental factors, is fostering the need for advanced treatment modalities such as radiotherapy, which is evolving as a crucial option to combat various types of cancer. Therefore, as healthcare providers continue to adopt these advanced treatment options, the radiotherapy market is anticipated to grow significantly.
 

Moreover, the rising public awareness pertaining to the various cancer treatment options including radiotherapy is a key catalyst for the growth of the market. Many government organizations and non-profit institutions undertake various awareness programs in order to educate individuals about the benefits of early disease diagnosis and related treatment options, such as cancer immunotherapy, which is estimated to reach USD 277.4 billion by 2032, radiotherapy, among others. For instance, the American Cancer Society (ACS) undertakes various awareness programs throughout the year, such as education pertaining to specific cancers, early detection methods, preventive strategies, and various available treatment options and their benefits. Such initiatives accelerate awareness of early cancer detection and treatment options for various cancers among individuals, thereby stimulating the adoption of advanced cancer therapies, such as radiotherapy, among healthcare professionals and patients, fostering market growth.
 

Radiotherapy Market Trends

• Increasing funding for healthcare infrastructure, treatments, research, and development activities pertaining to cancer is positively influencing the market growth.
   
• For instance, in India under the scheme of Rashtriya Arogya Nidhi (RAN), The Health Minister's Cancer Patient Fund (HMCPF) provides financial support of 5 lakh rupees for patients living below the poverty line and suffering from cancer. Moreover, the maximum upper limit of this aid that is permissible is INR 15 lakh rupees. This scheme covers 27 Regional Cancer Centers (RCCs) across the nation.
   
• Thus, such funding from government organizations stimulates the accessibility of advanced treatment options such as radiotherapy among the underserved population, thus propelling the growth of the market.
   
• Moreover, technological innovations in radiotherapy have significantly accelerated the growth of the market. Advancements such as intensity-modulated radiation therapy, image-guided radiation therapy, and proton therapy systems have enhanced and improved the precision of the treatment by targeting the cancerous cells without affecting the healthy non-cancerous cells. Therefore, this technological enhancement is fostering the adoption of radiotherapy as a preferred choice of treatment among patients suffering from cancer.
   

Trump Administration Tariffs

• Tariffs on Chinese imports, including critical components such as linear accelerators, high-voltage power supplies, and electronic control panels-many of which may be essential in radiotherapy system manufacturing-could raise production costs across the global radiotherapy market.
   
• A significant number of radiotherapy equipment manufacturers currently depend on China for cost-effective sourcing of these specialized parts. With the imposition of tariffs, international supply chains may experience disruption, potentially leading to higher equipment prices and delays in the development and deployment of radiotherapy solutions.
   
• Companies operating in the market may need to reevaluate their procurement and manufacturing strategies to minimize dependence on Chinese imports. This shift could drive gradual diversification toward alternative manufacturing hubs such as India, Vietnam, Mexico, and parts of Eastern Europe, which might offer more favorable trade conditions and competitive operational costs.
   
• In the short term, however, these strategic adjustments could present several challenges, including possible delays in onboarding new vendors, the potential need for requalification of alternative suppliers, and possible compatibility issues during the integration of critical subsystems such as radiation beam delivery units and imaging guidance modules.
   

Radiotherapy Market Analysis

The global market was estimated at USD 7.4 billion in 2024. Based on product type, the market is segmented into external beam radiation therapy, internal radiation therapy, and systemic radiation therapy. Furthermore, the external beam radiation therapy segment is further sub-segmented into intensity-modulated radiation therapy, image-guided radiation therapy, proton therapy, and other external beam radiation therapies. The external beam radiation therapy segment held revenues of USD 4.8 billion in the year 2024 and the segment is poised for significant growth at a CAGR of 5.9% during the forecast period.
 

• The rising prevalence of cancer, especially localized cancers such as breast, prostate, lung, colon, among other types of cancer, is a key catalyst for the growth of this segment.
   
• For instance, as per the 2022 report of Global Cancer Observatory, lung cancer was the most common type of cancer worldwide with 2.5 million cases, followed by breast cancer with 2.3 million cases, then colorectal cancer with 1.9 million cases, prostate cancer with 1.5 million cases, and stomach cancer with 970,000 cases.
   
• Thus, this rising prevalence of various cancers highlights the need for effective treatment options such as external beam radiation therapy, accelerating segmental growth.
   
• Moreover, the technological advancement in proton therapy, a type of external beam radiation therapy, is further pushing segmental growth in the forward direction.
   
• For instance, Varian’s ProBeam system which utilizes advanced technologies such as Pencil Beam Scanning (PBS) and Intensity Modulated Proton Therapy (IMPT), is designed for advanced photon therapy. This system is well known for its precision and can adapt to complex tumor geometries; such technological advancement is stimulating the market growth of the segment.
   

Based on application, the radiotherapy market is segmented into lung cancer, prostate cancer, breast cancer, cervical cancer, head and neck cancer, and other applications. The breast cancer segment dominated the market and was valued at USD 2.1 million in 2024 with the revenue share of 28.8%.
 

• The rising prevalence of breast cancer is one of the key catalysts for the growth of the segment.
   
• For instance, as per the data from the World Health Organization (WHO), in 2022, around 2.3 million women were diagnosed with breast cancer and approximately 670,000 died due to breast cancer globally.
   
• Moreover, according to the data from the American Cancer Society, in the U.S. it is projected that in 2025 around 316,950 women will be diagnosed with invasive breast cancer, about 59,080 women will be diagnosed with ductal carcinoma in situ, and approximately 42,170 women will die due to breast cancer across the nation.
   
• Thus, as the diagnosis rate of breast cancer increases, the need for effective treatment such as radiotherapy will increase, thereby propelling the market growth.
   

Based on end use, the radiotherapy market is segmented into hospitals, radiotherapy centers and ambulatory surgery centers, and cancer research institutes. The hospitals segment held the largest revenue of USD 3.1 billion in 2024.
 

• The growth of the segment is highly attributed to the availability of cutting-edge technologies in hospitals pertaining to radiotherapy, such as linear accelerators, proton therapy systems, among others.
   
• Moreover, hospitals are a one-stop destination for various cancer therapies such as chemotherapy, immunotherapy, and surgeries such as tumor resection, making this healthcare setting one of the most preferred options for the treatment of cancer among patients.
   
• Additionally, hospitals collaborate with manufacturers to develop technologically advanced radiotherapy systems, further solidifying their position in the fast-pacing market.
   
• For instance, in 2024, the Mayo Clinic and Varian Medical Systems collaborated to enhance their radiotherapy abilities. This partnership was intended to enhance Varian's radiotherapy technology to improve treatment efficacy, reduce side effects, and propel better patient outcomes. Therefore, collectively all these factors stimulate the growth of the hospital segment in the market.
   

The North America radiotherapy market is forecasted to reach USD 4.6 billion by 2034. The U.S. dominated the North America market with the largest revenue of USD 2.5 billion in 2024.
 

• The growing prevalence of cancer in the U.S. is the key catalyst for the growth of the market in the U.S.
   
• For instance, as per the data from the American Cancer Society, in 2025, around 2,041,910 new cases of cancer are to be diagnosed, and 618,120 cancer-related deaths are projected to occur in the U.S.
   
• Thus, the rising prevalence of cancer in the country is anticipated to stimulate the adoption of advanced treatment options such as radiotherapy, boosting market growth.
   

Europe: The radiotherapy market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The increasing investments from the UK government for improving cancer infrastructure, training programs pertaining to advanced devices and systems such as radiotherapy systems, and investment in modern equipment integrated with AI and machine learning are propelling the growth of the market in the country.
   
• For instance, in February 2025, the UK government announced an investment of 82.6 million pounds for integrating AI technology into cancer treatment and diagnosis.
   
• Thus, such investment is stimulating the advancement of cancer treatment and diagnosis, fostering the adoption of these innovative technologies among healthcare professionals, propelling the market growth in the country.
   

Asia Pacific: Japan radiotherapy market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The country has one of the speediest aging populations. The individuals of this demographic are highly prone to age-related chronic diseases such as cancer, thereby increasing the need for oncology treatments such as radiotherapy among them.
   
• For example, in 2023, projections from the World Economic Forum revealed that 1 in 10 people in Japan are aged 80 years and above, which is about one-third of the population.
   
• Thus, as the population ages in the country, so do the chances of cancer, thereby fostering market growth in the country.
   

Middle East and Africa: The radiotherapy market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The country's government, through various initiatives such as Vision 2030, is expanding the adoption of various cutting-edge technologies including innovative technologies pertaining to cancer treatment such as radiotherapy.
   
• Additionally, the country is prioritizing the establishment of specialized cancer treatment centers and launching public awareness campaigns to promote cancer prevention and early detection. These efforts are stimulating the demand for radiotherapy services in the country.
   

Radiotherapy Market Share

The top five players of the market account for approximately 80.5% of the market share, which includes companies such as Varian Medical Systems, Elekta, Curium, Accuray, and IBA Radiopharma Solutions. A crucial aspect of market strategy involves the frequent introduction of innovations such as proton therapy, intensity-modulated radiation therapy (IMRT), image-guided radiotherapy (IGRT), among others. Moreover, key industry players command considerable influence in this dynamic landscape, often propelling forward advancements through substantial investments in research and development. Additionally, strategic agreements, acquisitions, and mergers are involved in strengthening market positions and expanding global footprint along with the evolving regulatory landscapes.
 

Radiotherapy Market Companies

Some of the eminent market participants operating in the radiotherapy industry include:

• Accuray
• Brainlab
• Curium
• Canon Medical Systems
• Elekta
• Hitachi High-Tech
• IBA Radiopharma Solutions
• Isoray Inc.
• Mevion Medical Systems
• Mitsubishi Electric
• Nordion
• NTP Radioisotopes
• RefleXion
• Toshiba Energy Systems and Solutions
• Varian Medical Systems
   
• Varian Medical Systems has a strong global presence with 70 locations worldwide and a workforce of 11,000 employees, as per the company website.
   
• Elekta has a strong financial position; the company reported a total revenue of USD 1,699.1 million for the financial year 2023-2024.
   

Radiotherapy Industry News:

• In April 2024, GE Healthcare's subsidiary, MIM Software, deepened its collaboration with Elekta AB, aiming to enhance their radiation therapy software. This move expanded on an earlier agreement where GE Healthcare and Elekta primarily worked on supplying imaging and radiation therapy tools to hospitals.
   
• In May 2024, Elekta AB announced the acquisition of Philips Healthcare's Pinnacle Treatment Planning System (TPS) patent portfolio. This strategic acquisition strengthened Elekta's position in treatment planning and reinforced its commitment to leading innovation in the field of radiation therapy.

The radiotherapy market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• External beam radiation therapy
  • Intensity-modulated radiation therapy (IMRT)
  • Image-guided radiation therapy (IGRT)
  • Proton therapy
  • Other external radiation therapies
• Internal radiation therapy
• Systemic radiation therapy

Market, By Application

• Lung cancer
• Prostate cancer
• Breast cancer
• Cervical cancer
• Head and neck cancer
• Other applications

Market, By End Use

• Hospitals
• Radiotherapy centers and ambulatory surgery centers
• Cancer research institutes

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific 
  • China
  • India
  • Japan
  • Australia
• Latin America 
  • Brazil
  • Mexico
• Middle East and Africa 
  • Saudi Arabia
  • South Africa